Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
HIV Eradication: One Step Closer
Life Expectancy With HIV Increases Dramatically
Mouth Full of Problems: A Crisis in HIV Dental Care
New Technology Finds Meds That Might Flush Out Hidden HIV Reservoirs
New Hope for HIV Eradication
Personalized Therapeutic Vaccine Shows Promise
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

April 29, 2008

HIV Affects Body Shape and Lipids in Women

HIV-positive women, especially white women, are more likely than HIV-negative women to have belly fat accumulation and changes in cholesterol and triglycerides that indicate an increased risk for heart disease and strokes, say the authors of a study published in the May 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS). Although some antiretroviral (ARV) drugs can have an impact on lipids (cholesterol and triglycerides), HIV itself appears to exert a strong effect on women’s body shapes and triglyceride levels in particular.

Another recent study found unhealthy body shape changes in HIV-positive women. This study, however, which depended on simple waist and hip measurements, could not distinguish between the soft fat that sits just beneath the skin, called subcutaneous adipose tissue (SAT), and the more dense fat that sits deep in the body between the organs, called visceral adipose tissue (VAT). In HIV-negative people, increased VAT in the upper trunk, more so than SAT, has been strongly associated with increased heart disease risk.

Judith Currier, MD, of the Department of Medicine at the University of California Los Angeles, and her colleagues from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) study carried out sophisticated assessments of body fat using magnetic resonance imaging (MRI) scans and also measured lipids in both HIV-positive and HIV-negative women. Of the 129 HIV-negative women enrolled, the average age was 42 years, 49 percent were African American and 11 percent were current smokers. In comparison, the 157 HIV-positive women enrolled in the study had an average age of 39, 53 percent were African American and 11 percent were Hispanic. Forty-eight percent of the HIV-positive women were smokers, 73 percent were on ARV therapy, and their average CD4 count was 359.

Among the HIV-positive women, Currier’s group found that the African-American women had less VAT than the white women. The opposite was true, however, among the HIV-negative women. The HIV-positive women of both races had higher triglycerides than the HIV-negative women, and this difference held steady when the researchers controlled for a number of factors, including body fat composition. Having more upper trunk VAT, and less SAT in the legs, was associated with having higher triglycerides, as was having a high viral load.

Though ARV drugs had some impact on lipids—for instance, being on a protease inhibitor or efavirenz (found in Sustiva and Atripla) was associated with higher triglycerides; being on ritonavir (found in Norvir and Kaletra) was associated with higher low density lipoprotein (LDL) cholesterol; and being on Viramune (nevirapine) was associated with higher high density lipoprotein (HDL) cholesterol—Currier’s team points to the negative impact of viral load on lipids and hypothesizes that controlling HIV replication may help most to decrease the risk for heart disease and stroke in HIV-positive women. It should also be noted that HIV-positive women were nearly five times as likely as HIV-negative women to be smokers, which has been associated with body fat accumulation and lipid changes in studies of HIV-negative people; however, the authors did not report on the impact of smoking in this study.

Search: MRI, magnetic resonance imaging, FRAM, Judith Currier, UCLA, efavirenz, Sustiva, Atripla, ritonavir, Norvir, Kaletra, nevirapine, Viramune, smoking


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

BlackSouthAfricanMale, Durban, 2009-08-04 22:35:08
I've been on arv's (stavudine, lamuvudine & efavirenz) for 5 years now. Viral load is undetectable now and my CD4 count is more than 400. Two years ago I noticed a change in my body. My legs got thinner, buttocks got flat, stomach got bigger, arm got thinner and face neck and back of the neck got bigger. This has put stress in my life as people ask me what's going on. Sometimes my face gets so big I can't even go out without people starring at me.

Diane Miller, Albuquerque, 2008-05-01 16:57:27
Glad to see a study finally being done. I'm a 47 yr. old Caucasian, don't smoke nor drink and have been living with HIV for 13 yrs. and Type II Diabetes for 9 yrs. I've had Lipodystrophy for about 5 yrs. My stomach sticks out, so I get asked if I'm pregnant. It's very annoying. When I'm constipated, it sticks out even more. My drugs are Trizivir, Norvir, Prezisita, Insulin, Actos, Metformin, Zoloft, Tricor and Levoythroxine. CD4 is 640 and Viral Load is undetectable.

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy